

Trading by management and close relations to management

January 21, 2014

In accordance with section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions in Novozymes B shares (NZYM B, ISIN DK0060336014).

With reference to Company announcement No. 1, 2014, Novozymes' Executive Leadership Team has today from Novozymes A/S received the allocated stock from the incentive program for the period 2011-2013 following successful achievement of the targets set in the program. An overview of the number and value of shares allotted is provided below.

Recipient	No. of shares received in the program	Value of shares received in the program
Peder Holk Nielsen, CEO	125,075	DKK 29,805,373
Benny Loft, EVP & CFO	111,177	DKK 26,493,479
Thomas Videbæk, EVP, Business Development	111,177	DKK 26,493,479
Per Falholt, EVP, R&D	111,177	DKK 26,493,479
Thomas Nagy, EVP, Supply Operations	111,177	DKK 26,493,479
Andrew Fordyce, EVP, Business Operations	27,794	DKK 6,623,310

Contact information

Investor Relations:

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Press and media:

Rene Tronborg (DK)	+45 3077 2274	retr@novozymes.com
Frederik Bjoerndal (Europe)	+45 3077 0236	tfbh@novozymes.com
Paige Donnelly (USA)	+1 919 218 4501	pagd@novozymes.com
Meng Lian (China)	+86 136 9923 1164	mexl@novozymes.com
Henrique Pellini (Brazil)	+55 41 9288 0282	hqp@novozymes.com
Poonam Kapila (India)	+91 991 082 2339	poka@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.